Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    KEYNOTE 087
Previous Study | Return to List | Next Study

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02453594
Recruitment Status : Active, not recruiting
First Posted : May 25, 2015
Last Update Posted : April 19, 2021
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : April 20, 2022
Estimated Study Completion Date : April 20, 2022
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):